Veterinary evidence · 2023
The effect of anti-nerve growth factor monoclonal antibodies on the clinical signs of degenerative joint disease in cats.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Seeley Lydia
Аннотация
PICO QUESTION: Are felinised anti-nerve growth factor monoclonal antibodies (frunevetmab) effective at reducing the clinical signs of pain and immobility in cats with degenerative joint disease when compared with no treatment?
CATEGORY OF RESEARCH: Treatment.
NUMBER AND TYPE OF STUDY DESIGNS REVIEWED: Three peer-reviewed randomised controlled trial treatment studies, two of which were pilot studies.
STRENGTH OF EVIDENCE: Moderate.
OUTCOMES REPORTED: All three studies concluded that there was a statistical reduction in pain and an improvement in mobility in the groups administered frunevetmab, when compared to the groups administered the placebo.
CONCLUSION: There is moderate evidence suggesting that the administration of frunevetmab by injection led to a reduction in pain and an increase in mobility. Injections were given at day 0; day 0 and 28, or day 0, 28 and 56 depending on the study. Further research should be conducted to ensure repeatability, involving more objectively measured outcomes to reduce the reliance on subjective measures which are more likely to have associated bias.
CATEGORY OF RESEARCH: Treatment.
NUMBER AND TYPE OF STUDY DESIGNS REVIEWED: Three peer-reviewed randomised controlled trial treatment studies, two of which were pilot studies.
STRENGTH OF EVIDENCE: Moderate.
OUTCOMES REPORTED: All three studies concluded that there was a statistical reduction in pain and an improvement in mobility in the groups administered frunevetmab, when compared to the groups administered the placebo.
CONCLUSION: There is moderate evidence suggesting that the administration of frunevetmab by injection led to a reduction in pain and an increase in mobility. Injections were given at day 0; day 0 and 28, or day 0, 28 and 56 depending on the study. Further research should be conducted to ensure repeatability, involving more objectively measured outcomes to reduce the reliance on subjective measures which are more likely to have associated bias.